Related Experiment Video

Updated: May 17, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Matrix metalloproteinase-3 (MMP-3) -1612 5A/6A promoter polymorphism in coronary artery disease in Indian population

Kavita K Shalia1, V K Shah, M R Mashru

  • 1Sir H. N. Medical Research Society, Sir H. N. Hospital and Research Centre, Raja Rammohan Roy Road, Mumbai, 400 004 India.

Indian Journal of Clinical Biochemistry : IJCB
|October 30, 2012
PubMed

Insights

The 5A/6A polymorphism in matrix metalloproteinase-3 (MMP-3) showed no association with coronary artery disease (CAD) in an Indian population. However, elevated serum MMP-3 levels were observed in acute myocardial infarction patients, particularly those with the 6A genotype.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Biochemistry

Background:

  • Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of coronary artery disease (CAD).
  • The -1612 5A/6A polymorphism of MMP-3 influences gene activity, with the 5A allele exhibiting higher activity than the 6A allele.
  • Understanding the genetic predisposition to CAD is crucial for effective prevention and treatment strategies.

Purpose of the Study:

  • To investigate the association between the MMP-3 5A/6A polymorphism and CAD in an Indian population.
  • To evaluate serum MMP-3 levels in different CAD patient groups and healthy controls.

Main Methods:

  • Genotyping of the MMP-3 5A/6A polymorphism was performed using a PCR-based restriction digestion method.
  • Study participants included patients with stable angina, unstable angina, recent myocardial infarction (MI), acute MI, and healthy controls.
  • Serum MMP-3 levels were quantified and compared across the groups.

Main Results:

  • The genotype distribution of the MMP-3 5A/6A polymorphism did not differ significantly between CAD patient groups and controls.
  • Serum MMP-3 levels were significantly elevated by 36.8% in patients presenting with acute MI compared to controls (P=0.031).
  • Elevated serum MMP-3 levels in acute MI patients showed a stronger association with the 6A genotype, suggesting a potential discrepancy with in vitro findings.

Conclusions:

  • The MMP-3 5A/6A polymorphism is not significantly associated with CAD in the studied Indian population.
  • Elevated serum MMP-3 levels at the time of acute myocardial infarction are a relevant finding, particularly in individuals with the 6A genotype.
  • Further research is warranted to reconcile the observed association between peripheral MMP-3 levels and genotypes with in vitro functional data.
Keywords:
Coronary artery diseaseMatrix metalloproteinase-3Myocardial infarctionSingle nucleotide polymorphismStable anginaUnstable angina

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...